Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)

Watch this presentation to learn • Overview of the SNDS and the key working practices to access the database and ongoing SNDS developments • Similarities and differences between SNDS and other claims databases • Strengths and opportunities for HTAs and market access in Europe through case studies • Stakeholder perspectives: current and potential benefits to … Continued

Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier

First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress PRINCETON, NJ – May 4, 2021, Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of its Secondary Intelligence™ software, the first and only software that quantitatively predicts the risk of adverse effects and safety issues derived from … Continued

The Wizard of Oligos: There’s no place like having a successful drug development program!

Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range of diseases— are experiencing tremendous growth in the pharmaceutical industry. But, performing the needed PK/PD and clinical pharmacology assessments to optimize the safety and efficacy of investigational oligonucleotide candidates and gain regulatory approval can be challenging. It’s enough to make … Continued

The Promises and Pitfalls of Gene Therapy for Rare Diseases

The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have raised questions about its promise. With only two gene therapies FDA-approved for rare diseases to date, the path to developing these medicines is still a difficult one. This presentation exploreed how the biopharma industry can overcome development challenges in the … Continued

1 of 13
Back to top
Powered by Translations.com GlobalLink OneLink Software